The First Hearing Loss Cure | FX-322 Update | Frequency Therapeutics

FX-322 is a new pharmaceutical research drug aimed at finding a hearing loss cure. The research group Frequency Therapeutics created FX 322 to help find a cure for individuals with hearing loss. In this video, I share an update on the research.

There could be drug solutions that can treat and cure hearing loss in the next 20 years. This is pretty exciting and it’s never happened before. In this article, I’m going to give an update on FX-322, a drug created by Frequency Therapeutics. I’ll explain what significance this has for someone who may have hearing loss or tinnitus.

Hi, my name is Ben Thompson. I’m an audiologist and founder of PureTinnitus. Today I’m going to give you an update on FX-322 by Frequency Therapeutics and the effectiveness that it’s shown in the trials so far, as well as my own personal opinion about how I think this might help someone who has hearing loss or tinnitus in the future. Could this actually be some form of a cure for hearing loss or tinnitus? Let’s get into it.

Dr. Thompson explains FX-322 and it’s implications for tinnitus patients.

FX-322: Can It Cure Tinnitus?

Let’s look at the Frequency Therapeutics website to see what they’re up to, and if FX-322 can actually cure hearing loss and tinnitus, naturally repairing or reversing damage caused by degenerative disease. This is referring to age-related or sensorineural hearing loss.

Phase 1b looked at patients with mild to moderately severe age-related hearing loss, ages 66 to 85. Another 1b study looked at patients with severe hearing loss ages 18 to 65. In an article from Otology & Neurotology, which was published February 22, 2021, Frequency Therapeutics’ results are about improving speech intelligibility in subjects with stable sensorineural hearing loss, the most common type of hearing loss, following an intratympanic dosing of FX-322. In a study, intratympanic dosing means putting the drug through the eardrum and having it affect the inner hearing organ, the cochlea.

This study was mainly composed of guinea pigs, which are the most commonly tested animal to replicate the human cochlea, but they also did some intratympanic dosing with humans. Most importantly, this study was a randomized, double-blind, placebo-controlled clinical trial in three different ENT clinics in the US. The individuals in this study were diagnosed with mild to moderately severe sensorineural hearing loss in one or both ears for more than six months. Six real patients were given this dose. Out of the six, four showed clinically significant improvements, meaning that their word recognition scores improved between 18% and 42%, while no significant changes were observed in the placebo group. So there were improvements here for the FX-322 subjects in this newest, most recent study, for word recognition in quiet settings, as well as for speech understanding through background noise. Both of these are very significant.

The conclusions of this study show that the delivery of FX-322 to the extended high-frequency region of the cochlea is well-tolerated and enhances speech recognition performance in multiple subjects with stable chronic hearing loss.

Can Progenitor Cells Cure Hearing Loss or Tinnitus?

Looking at FX-322 specifically, this is coined as a new class of therapeutics designed to activate progenitor cells. Progenitor cells are similar to stem cells but are programmed to create specific cell types. These cells remain active and regenerate in some organs and tissues, while becoming dormant in others. The research so far has shown some improvement in the patients studied for FX-322.

So keep an eye out for Frequency Therapeutics and keep following, where I’m going to give updates as they release the data and analyses coming out from all these studies. I’m certainly hopeful that these kinds of drugs can help someone who is struggling with tinnitus and hearing loss.

Now if you have one of those conditions, you need to know that if this drug got released and approved for some kinds of hearing loss or some kinds of tinnitus, it would likely start with a very small section of people. They would test that, gathering as much data and information as they could get, before they would have the confidence to start opening it up to more people. For that reason, even if FX-322 is proven effective, it will take years to actually be released to the general public. But you can guarantee that I’ll be monitoring this over time and giving you, my audience, updates to make sure you stay in the loop.

To learn what may help you manage your tinnitus, please download our free 10-page e-book, The Ultimate Guide to Tinnitus Relief. Dr. Thompson also offers online Tinnitus Retraining Therapy with Pure Tinnitus.

Dr. Ben Thompson, Au.D.

Dr. Ben Thompson, Au.D.

Dr. Ben Thompson is an audiologist in California and founder of Pure Tinnitus. Dr. Thompson has a comprehensive knowledge of tinnitus management. He completed his residency at University of California at San Francisco (UCSF) and is a past board member of the California Academy of Audiology. Via telehealth, Dr. Thompson provides services to patients with hearing loss and tinnitus.

You may also like